Organovo Holdings, Inc. (ONVO) EPS Estimated At $-0.10

January 20, 2018 - By Louis Casey

 Organovo Holdings, Inc. (ONVO) EPS Estimated At $ 0.10
Investors sentiment decreased to 1.53 in Q3 2017. Its down 0.02, from 1.55 in 2017Q2. It worsened, as 11 investors sold Organovo Holdings, Inc. shares while 19 reduced holdings. 11 funds opened positions while 35 raised stakes. 24.05 million shares or 7.12% more from 22.45 million shares in 2017Q2 were reported.
2,000 are held by West Oak Ltd Liability. Legal And General Gp Public Limited Co reported 32,028 shares. Credit Suisse Ag reported 131,036 shares. Amer Finance Gru reported 251,500 shares stake. Bridgeway Management invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Royal Bank & Trust Of Canada invested in 0% or 16,092 shares. Susquehanna Grp Inc Llp owns 208,910 shares or 0% of their US portfolio. The Texas-based Next Grp Incorporated has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Raymond James And Associate invested 0% of its portfolio in Organovo Holdings, Inc. (NASDAQ:ONVO). National Bank & Trust Of New York Mellon holds 0% of its portfolio in Organovo Holdings, Inc. (NASDAQ:ONVO) for 426,111 shares. State Of Wisconsin Inv Board invested in 75,000 shares. Carroll Financial Assocs Inc holds 0% or 1,000 shares in its portfolio. Metropolitan Life Insurance stated it has 55,744 shares or 0% of all its holdings. Focused Wealth Management stated it has 2,000 shares or 0% of all its holdings. Wealthtrust reported 2,610 shares.

Analysts expect Organovo Holdings, Inc. (NASDAQ:ONVO) to report $-0.10 EPS on February, 8.They anticipate $0.01 EPS change or 11.11 % from last quarter’s $-0.09 EPS. After having $-0.09 EPS previously, Organovo Holdings, Inc.’s analysts see 11.11 % EPS growth. The stock increased 2.92% or $0.04 during the last trading session, reaching $1.41. About 1.43M shares traded or 7.55% up from the average. Organovo Holdings, Inc. (NASDAQ:ONVO) has risen 12.50% since January 20, 2017 and is uptrending. It has underperformed by 4.20% the S&P500.

Organovo Holdings, Inc., an early commercial stage company, creates and creates functional and three-dimensional human tissues for use in medical research and therapeutic applications. The company has market cap of $150.76 million. The firm develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. It currently has negative earnings. The Company’s 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

More recent Organovo Holdings, Inc. (NASDAQ:ONVO) news were published by: Globenewswire.com which released: “Organovo Receives Orphan Designation From US FDA for 3D Bioprinted Therapeutic …” on December 26, 2017. Also Prnewswire.com published the news titled: “What’s Happening With These Medical Research Stocks? — Organovo, BioTelemetry …” on January 18, 2018. Globenewswire.com‘s news article titled: “Organovo Announces Release Date for Fiscal Third-Quarter 2018 Financial Results” with publication date: January 18, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.